LAB — STANDARD BIOTOOLS INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1162194 ·
Last close
$0.54
Market Cap
$212.95M
52W High
$1.72
52W Low
$0.39
ADV30
956,869
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 19,385,000 10,828,000 -8,093,000 13,483,000 635,332,000 267,487,000 79,582,000
Jun 2026 20,104,000 10,535,000 -7,829,000 -26,758,000 627,218,000 270,026,000 87,247,000
Mar 2026 21,146,000 11,308,000 -9,416,000 127,068,000 639,114,000 265,772,000 77,991,000
Dec 2025 23,795,000 11,382,000 -21,924,000 19,283,000 567,754,000 120,863,000 143,463,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-64,259,000
Investing CF
$202,291,000
Financing CF
$-156,000
CapEx
$-2,276,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.34
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,146,754,000
Inventory
$17,617,000
Receivables
$12,982,000
ST Investments
$193,624,000
EBIT TTM
$-47,364,000
Pretax Income TTM
$-73,031,000
Interest Exp TTM
$26,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$84,430,000
EBITDA
$-38,092,000
Free Cash Flow
$166,871,248
Enterprise Value
$-183,190,272
Total Cash
$461,111,008
Total Debt
$26,834,000
Shares Out
394,790,441
Trailing EPS
$-0.09
Book Value
$1.41
ROE
-7.8%
ROA
-5.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 85,331,000 -93,305,000 -74,896,000 567,754,000 143,463,000 424,291,000 -74,343,000
Dec 2024 91,008,000 -87,006,000 -138,885,000 612,345,000 140,623,000 471,722,000 -143,454,000
Dec 2023 106,340,000 -63,039,000 -74,656,000 323,067,000 471,118,000 -148,051,000 -43,287,000
Dec 2022 97,948,000 -102,616,000 -190,098,000 390,310,000 471,777,000 -81,467,000 -89,370,000

TTM Snapshot

Revenues TTM
$64,024,000
NetIncome TTM
$84,906,000
OpCashFlow TTM
—
Assets (Latest)
$627,218,000
Forward EPS
$-0.01

Max Pain — expiry 2027-02-19

max pain strike: $0.50 · spot: $0.57 · call oi: 1,316 · put oi: 12

Peers — same industry

TickerNameMarket CapLastDaily %
NGEN NERVGEN PHARMA CORP. $210.74M $1.96 —
PRLD Prelude Therapeutics Inc $216.05M $3.32 —
ACIU AC Immune SA $209.79M $2.11 —
CYPH CYPHERPUNK TECHNOLOGIES INC. $205.29M $1.90 —
KROS Keros Therapeutics, Inc. $221.95M $11.31 —

News headlines (Yahoo Finance, 1h cache)

ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific
2026-11-03 12:30 · Yahoo
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
2026-10-05 20:05 · Yahoo
Standard BioTools Provides Update on Sale of Mass Cytometry Business
2026-09-30 20:42 · Yahoo
Standard BioTools Reports Second Quarter 2026 Financial Results
2026-08-05 20:05 · Yahoo
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
2026-07-28 14:26 · Yahoo
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
2026-07-28 12:00 · Yahoo
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
2026-07-20 11:30 · Yahoo
Standard BioTools Reports First Quarter 2026 Financial Results
2026-05-05 20:05 · Yahoo
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-06 00:30 · Yahoo
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
2026-04-21 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.